Moneycontrol PRO

you are here: HomeNewsBusinessEarningsDishman Pharma post standalone Q2 PAT at Rs 13.52cr sans Fx

SHOW NAMES

Trending Topics

business

Dishman Pharma post standalone Q2 PAT at Rs 13.52cr sans Fx

Arpit Vyas, MD of Dishman Pharma presents his views on the company‘s quarterly earnings, in an interview to CNBC-TV18.

first published: Oct 31, 2013 07:34 pm

LATEST VIDEOS

A collection of the most-viewed Moneycontrol videos.

Sensex, Nifty resume rally after 2-day pause, financials shine bright | Closing Bell
Maran Govindasamy of Unifi Capital on Investment Insights from India’s Consumption Story
Nifty Bulls Likely To Tread With Caution With Eye On Axis Bank Q2 Earnings |Opening Bell Live
Live: Nifty slips below 25,200, LG Electronics shares down after blockbuster debut | Closing Bell

Watch and Follow our leading shows

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347